ZA200610578B - Ligands binding the complex of urokinase-type plasminogen activator (UPA) and its receptor (UPAR) that inhibit downstream upar interactions: Identification and use in diagnosis or therapy - Google Patents

Ligands binding the complex of urokinase-type plasminogen activator (UPA) and its receptor (UPAR) that inhibit downstream upar interactions: Identification and use in diagnosis or therapy

Info

Publication number
ZA200610578B
ZA200610578B ZA200610578A ZA200610578A ZA200610578B ZA 200610578 B ZA200610578 B ZA 200610578B ZA 200610578 A ZA200610578 A ZA 200610578A ZA 200610578 A ZA200610578 A ZA 200610578A ZA 200610578 B ZA200610578 B ZA 200610578B
Authority
ZA
South Africa
Prior art keywords
upar
upa
urokinase
diagnosis
receptor
Prior art date
Application number
ZA200610578A
Other languages
English (en)
Inventor
Graham C Parry
Andrew P Mazar
Original Assignee
Attenuon Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Attenuon Llc filed Critical Attenuon Llc
Publication of ZA200610578B publication Critical patent/ZA200610578B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
ZA200610578A 2004-05-25 2005-05-25 Ligands binding the complex of urokinase-type plasminogen activator (UPA) and its receptor (UPAR) that inhibit downstream upar interactions: Identification and use in diagnosis or therapy ZA200610578B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57389604P 2004-05-25 2004-05-25

Publications (1)

Publication Number Publication Date
ZA200610578B true ZA200610578B (en) 2009-09-30

Family

ID=35451457

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200610578A ZA200610578B (en) 2004-05-25 2005-05-25 Ligands binding the complex of urokinase-type plasminogen activator (UPA) and its receptor (UPAR) that inhibit downstream upar interactions: Identification and use in diagnosis or therapy

Country Status (16)

Country Link
US (1) US8101726B2 (https=)
EP (1) EP1765397B1 (https=)
JP (1) JP4890449B2 (https=)
KR (1) KR20070047246A (https=)
CN (1) CN101022830A (https=)
AU (1) AU2005248400A1 (https=)
CA (1) CA2568428C (https=)
DK (1) DK1765397T3 (https=)
ES (1) ES2398221T3 (https=)
IL (1) IL179565A0 (https=)
MX (1) MXPA06013709A (https=)
PL (1) PL1765397T3 (https=)
PT (1) PT1765397E (https=)
RU (1) RU2006145905A (https=)
WO (1) WO2005116077A2 (https=)
ZA (1) ZA200610578B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343489B2 (en) * 2006-03-21 2013-01-01 Weaver David T Methods for humanizing antibodies and humanized antibodies made thereby
CN1919874B (zh) * 2006-09-18 2010-09-08 中国人民解放军军事医学科学院生物工程研究所 一种抗尿激酶型纤溶酶激活剂受体的抗体样分子ATF-Fc融合蛋白及其用途
DK2117571T3 (en) * 2006-12-08 2017-05-08 Monopar Therapeutics Inc Urokinase-type plasminogen activator receptor epitope
US8815519B2 (en) * 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
ES2457822T3 (es) 2007-11-08 2014-04-29 The General Hospital Corporation Procedimientos y composiciones de tratamiento de enfermedades proteinúricas
CA2779958A1 (en) 2008-11-06 2010-05-14 University Of Miami Role of soluble upar in the pathogenesis of proteinuric kidney disease
CN102597775A (zh) 2009-09-25 2012-07-18 佐马技术有限公司 筛选方法
JP2014502965A (ja) 2010-12-22 2014-02-06 イフォム・フォンダツィオーネ・インスティトゥオ・フィルチ・ディ・オンコロジア・モレコラーレ ｕＰＡＲアンタゴニストおよびその使用
DK3252076T3 (da) 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
US20130344074A1 (en) 2011-03-16 2013-12-26 Sanofi Uses of a dual v region antibody-like protein
JP6055464B2 (ja) 2011-05-09 2016-12-27 ザ ユニバーシティー オブ マイアミ 循環血中の可溶性ウロキナーゼ受容体の低減
WO2013020898A1 (en) 2011-08-05 2013-02-14 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Constitutively active upar variants and their use for the generation and isolation of inhibitory antibodies
CN110201144B (zh) * 2013-03-15 2024-01-02 得克萨斯州大学系统董事会 用Nutlin-3a和肽抑制肺纤维化
CN105368859B (zh) * 2015-11-25 2019-10-18 王任直 一种嵌合抗原受体hCD87-CAR及载有hCD87-CAR基因结构的慢病毒及质粒及其应用
US10959062B1 (en) 2018-04-19 2021-03-23 Tango Tango, Inc. System and method for push-to-talk over cellular integration with software defined radio
US10681506B1 (en) 2018-04-19 2020-06-09 Tango Tango, Inc. System and method for push-to-talk over cellular integration with software defined radio
AU2019339260B2 (en) 2018-09-10 2025-06-26 Rein Therapeutics, Inc. Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis
WO2020069498A1 (en) 2018-09-28 2020-04-02 Jochen Reiser Supar and prediction and treatment of acute kidney injury
US20230220112A1 (en) * 2019-10-28 2023-07-13 Monash University Antibodies for binding plasmin
CA3182769A1 (en) * 2020-06-15 2021-12-23 Andrew P. Mazar Precision radioimmunotherapeutic targeting of the urokinase plasminogen activator receptor (upar) for treatment of severe covid-19 disease
IL306074A (en) * 2021-03-24 2023-11-01 Alkermes Inc UPAR antibodies and fusion proteins with them
JP2024520180A (ja) * 2021-05-21 2024-05-21 ノーススター メディカル テクノロジーズ リミテッド ライアビリティ カンパニー ウロキナーゼプラスミノーゲンアクチベーター受容体標的放射性医薬品
AU2022287975A1 (en) * 2021-06-11 2023-12-14 Memorial Hospital For Cancer And Allied Diseases Antigen recognizing receptors targeting upar and uses thereof
CA3246325A1 (en) * 2022-03-24 2023-09-28 The United States Government As Represented By The Department Of Veterans Affairs Urokinase-type plasminogen activator receptor-binding peptides and methods of use
EP4610269A1 (en) 2024-02-29 2025-09-03 3B Pharmaceuticals GmbH Urokinase plasminogen activator surface receptor (upar) ligands for diagnostic or therapeutic use
WO2025207781A1 (en) 2024-03-26 2025-10-02 Monopar Therapeutics Inc. Antibody radioisotope constructs
WO2026019458A1 (en) 2024-07-19 2026-01-22 Monopar Therpeutics, Inc Squaramide bi-functional chelators and associated radiopharmaceuticals and methods of use
CN121248786A (zh) * 2025-12-08 2026-01-02 上海宏成药业有限公司 抗尿激酶纤溶酶原激活物受体抗体及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532132A (en) * 1993-09-28 1996-07-02 President And Fellows Of Harvard University Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor
DE10117381A1 (de) * 2001-04-06 2002-10-10 Wilex Biotechnology Gmbh Herstellung polyklonaler, monospezifischer Antikörper gegen die uPAR-Varianten del4, del5 und del4+5 sowie deren Verwendung für diagnostische und therapeutische Zwecke
US20030219837A1 (en) * 2002-03-18 2003-11-27 Cress Anne E. Integrin ligand
DK2117571T3 (en) * 2006-12-08 2017-05-08 Monopar Therapeutics Inc Urokinase-type plasminogen activator receptor epitope

Also Published As

Publication number Publication date
EP1765397A2 (en) 2007-03-28
CA2568428C (en) 2020-12-29
IL179565A0 (en) 2007-05-15
US8101726B2 (en) 2012-01-24
EP1765397A4 (en) 2009-05-13
MXPA06013709A (es) 2008-01-16
CA2568428A1 (en) 2005-12-08
RU2006145905A (ru) 2008-06-27
JP2008509086A (ja) 2008-03-27
WO2005116077A3 (en) 2005-12-29
AU2005248400A1 (en) 2005-12-08
ES2398221T3 (es) 2013-03-14
WO2005116077A2 (en) 2005-12-08
PL1765397T3 (pl) 2013-04-30
KR20070047246A (ko) 2007-05-04
EP1765397B1 (en) 2012-10-24
CN101022830A (zh) 2007-08-22
JP4890449B2 (ja) 2012-03-07
DK1765397T3 (da) 2013-02-04
PT1765397E (pt) 2013-02-04
US20090180952A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
IL179565A0 (en) LIGANDS BINDING THE COMPLEX OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (uPA) AND ITS RECEPTOR (uPAR) THAT INHIBIT DOWNSTREAM uPAR INTERACTIONS: IDENTIFICATION AND USE IN DIAGNOSIS OR THERAPY
EP1747522A4 (en) METHODS AND SYSTEMS FOR ENSURING GUARANTEED COMMERCIAL TRANSACTIONS
IL199045A0 (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
WO2008073312A3 (en) Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
IL190332A0 (en) Human antibodies against il13 and therapeutic uses
SG10201608268RA (en) Human antibodies that bind cxcr4 and uses thereof
IL209951A (en) Use of n-butyl-dioxinogirimycin and enzyme replacement therapy to make a drug for the treatment of pomp
EP2070917A4 (en) TASTE-ANIMATING MEANS AND THESE FOODS OR BEVERAGES CONTAINED
ZA200902419B (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
WO2008125116A3 (en) Upar inhibition
ZA200800863B (en) Methods for determining the effect of a treatment on the cross-B structure content of a protein; selection of treatments and uses thereof
EP2012798A4 (en) USE OF INOSITOL-TRIPYROPHOSPHATE IN THE TREATMENT OF TUMORS AND DISEASES
IL181126A0 (en) Preparation of gold-containing nano-liposome particles and their use in medical therapy
EP1874800A4 (en) DIAGNOSTIC AND THERAPEUTIC AGENTS
IL163900A (en) Antibody which binds to tpte for use in diagnosing, monitoring, preventing or treating cancer disease and pharmaceutical compositions comprising said antibody
EP1809603A4 (en) NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY
EP2112902A4 (en) METHOD AND MEANS FOR MEASURING THE SYSTOLIC BLOOD PRESSURE IN THE FOOT CONTROL
AU2003227148A8 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
WO2007149935A3 (en) Methods and compositions for modulating hepsin activation of urokinase-type plasminogen activator
GB201020621D0 (en) Pin for hygienic and/or medical use in the anal region
IL197509A0 (en) Therapeutic and/or ameliorating agent for disseminated intravascular coagulation
SI1639013T1 (sl) Pan-kir2dl nk-receptorska protitelesca in njihova uporaba pri diagnosticiranju in terapiji
EP1721616A4 (en) TREATMENT AND FOOD TO TREAT TIREDNESS
AU2003245858A8 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases